×
Stock Information
Share Data
Stock Performance
SEC Filings
Analyst Coverage
Advisor & Investor Contacts

Reports & Presentations

Interim & Annual Reports
Presentations
Corporate Governance
Company Information
Leadership
Board of Directors
General Meetings

Media

Press Releases
In the News
biodexa logo
  • About
    • Our Mission
    • Leadership
    • Board of Directors
    • Careers
  • Pipeline
  • Clinical Trials
  • Press Releases
  • Investors
    • Stock Information
    • Reports & Presentations
    • Corporate Governance
    • Press Releases
    • SEC Filings
  • Patient Resources
  • Contact

Video – AGM 2023

9th June 2023

Recent Posts

  • Biodexa Enters Into Warrant Exercise Transaction for $2.3 Million in Gross Proceeds
  • Interim results for the six months ended June 30, 2026
  • Biodexa announces major milestone for its Serenta registrational Phase 3 trial in FAP
  • Result of General Meeting
  • Biodexa Initiates Support Activities for FAP Patients and Treatment Centers in France
logo white

Biodexa Pharmaceuticals PLC (listed on NASDAQ: BDRX) is a clinical stage biopharmaceutical company developing a pipeline of treatments aimed at diseases with high unmet clinical need. The company’s lead development programme, eRapa, is being readied for a phase 3 registration study in familial adenomatous polyposis (FAP), a rare and serious condition where the only successful treatment option is bowel resection. Without effective treatment virtually all FAP patients progress to develop colorectal cancer. The company is also working on treatments for type 1 diabetes and primary and metastatic cancers of the brain.

  • Follow
  • Follow

Code of Business Conduct and Ethics   |  Privacy Policy   |   Terms and Conditions |   Cookies

© Copyright 2026 Biodexa Pharmaceuticals PLC.

Website by Alpha Pixa.

Manage Cookie Consent
To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behaviour or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Functional Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes. The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
  • Manage options
  • Manage services
  • Manage {vendor_count} vendors
  • Read more about these purposes
View preferences
  • {title}
  • {title}
  • {title}